[PRESS RELEASE] – TORONTO, May 26, 2025 – MediPharm Labs Corp., a pharmaceutical company specialized in precision-based cannabinoids, announced it has begun production on novel cannabis metered dose inhalers for the European Union and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited, MediPharm’s exclusive sales and distribution partner in those territories.
This discreet and innovative product provides patients with a smoke-free option when seeking fast onset of effects without combustion or heating. The cannabis metered dose inhaler, manufactured by MediPharm Labs under Good Manufacturing Practices (GMP), delivers a precise dose of cannabis active pharmaceutical ingredients (API) with GMP-qualified components and excipients.
MediPharm Labs has launched metered dose inhalers in the Canadian adult-use and wellness and medical channels and expects to launch in Australia, the EU and the United Kingdom in Q3 of 2025.
Management Commentary:
David Pidduck, CEO of MediPharm Labs, said, "We’re excited to expand our international portfolio and partner with Blackpoint to bring our innovative cannabis metered dose inhaler to the EU and United Kingdom. This smoke- and vapor-free format supports our mission to advance global access to pharma-grade cannabinoid wellness products. Successfully launching in these markets reflects the strength of our global execution strategy and our ability to manage the complexities of international compliance, logistics, and market access.”
David Martinez, CEO of Blackpoint, said, "Working together with the highly capable team at MediPharm is exciting, and we look forward to introducing our novel and much-needed metered dose products for the benefit of the growing number of patients across the EU and United Kingdom.”
Additional highlights:
- EU and United Kingdom Exclusive Supply and Distribution: MediPharm Labs is the exclusive supplier and manufacturer of the cannabis metered dose inhaler to Blackpoint and will leverage its relationships and distribution in the EU and the United Kingdom. Prohibition Partners estimated the European medicinal cannabis market to be worth €834 million in 2024. The agreement with Blackpoint includes minimum purchase obligations to ensure a steady supply of the product in the designated markets.
- Innovative Delivery Method: The metered dose inhaler offers a precise and repeatable dose of cannabis API, ensuring consistent and reliable patient outcomes without the stigma, smell or by-products of smoking or vaping.
- GMP Manufacturing: The product is manufactured under stringent GMP standards, ensuring the highest quality and safety for medical use. MediPharm’s multiple GMP certifications and global reach will enable the company to launch the product internationally.
- Medical Applications: The inhaler is designed for medical applications, providing a discreet, familiar and effective delivery method for patients, similar to the metered dose inhaler format used in asthma treatments.
